Dova Pharmaceuticals

Dova Pharmaceuticals is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate includes avatrombopag, which is an orally administered thrombopoietin receptor agonist, or TPO-RA, that the company is developing for the treatment of thrombocytopenia. As of Dec 31 2017, avatrombopag has been evaluated in one Phase 3 clinical trial and two Phase 2 clinical trials for the treatment of adults with chronic immune thrombocytopenic purpura.
  • TickerDOVA
  • ISINUS25985T1025
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Laura Chico

On the Road Again... DOVA Management Travel Arrives at Opportune Time

1 director sold

A director at Dova Pharmaceuticals Inc sold 7,580 shares at 15.259USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Wedbush Research

DOVA_20190716

Laura Chico

On the Road Again... DOVA Management Travel Arrives at Opportune Time

Wedbush Research

DOVA_20190716

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

1 director sold

A director at Dova Pharmaceuticals Inc sold 7,580 shares at 15.259USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ValuEngine Rating and Forecast Report for DOVA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch